A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics
and activity of escalating, multiple, oral doses of GS-5885 in subjects with chronic genotype
1 Hepatitis C Virus (HCV) infection. Each participant in the study will be sequestered in the
clinic for the initial 5 days of the study.